This is a summary of the European public assessment report (EPAR) for Methylthioninium chloride Proveblue. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and itsconditions of use. It is not intended to provide practical advice on how to use Methylthioninium chloride Proveblue For practical information about using Methylthioninium chloride Proveblue, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Acute symptomatic treatment of medicinal and chemical products- induced methaemoglobinaemia. Methylthioninium chloride Proveblue is indicated in adults, children and adolescents (aged 0 to 17 years old).
Therapeutic Area (MeSH)
ATC Code
V03AB17
ATC Item
methylthioninium chloride
Pharmacotherapeutic Group
All other therapeutic products
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| methylthioninium chloride | N/A | 亚甲蓝 |
EMA Name
Methylthioninium chloride Proveblue
Medicine Name
Methylthioninium chloride Proveblue
Aliases
N/ANo risk management plan link.
